

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7398182

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>SEQUENCE:</b>	1

**CONVEYING PARTY DATA**

Name	Execution Date
ONCOQUEST PHARMACEUTICALS INC.	06/20/2022

**RECEIVING PARTY DATA**

<b>Name:</b>	OQP BIO INC.
<b>Street Address:</b>	BONSOL BUILDING 445, TEHERAN-RO, GANGNAM-GU
<b>Internal Address:</b>	4TH FLOOR
<b>City:</b>	SEOUL
<b>State/Country:</b>	KOREA, REPUBLIC OF

**PROPERTY NUMBERS Total: 19**

Property Type	Number
Patent Number:	6716966
Patent Number:	7147850
Patent Number:	6689355
Patent Number:	8038994
Patent Number:	6241985
Patent Number:	8945566
Patent Number:	8697079
Patent Number:	10392444
Application Number:	62034915
Patent Number:	10975163
Application Number:	62103758
Patent Number:	10537636
Patent Number:	11351255
Application Number:	62455114
Application Number:	63159013
Application Number:	63318835
Application Number:	17406171
Application Number:	63237634
Application Number:	63320844

PATENT

**CORRESPONDENCE DATA****Fax Number:** (514)448-4607*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 514-658-4844**Email:** mathieu@benoit-cote.com**Correspondent Name:** BENOIT & COTE INC.**Address Line 1:** 300-560 CREMAZIE BLVD. EAST**Address Line 4:** MONTREAL, CANADA H2P 1E8

<b>ATTORNEY DOCKET NUMBER:</b>	G2204CA00
<b>NAME OF SUBMITTER:</b>	MATHIEU MIRON
<b>SIGNATURE:</b>	/MATHIEU MIRON/
<b>DATE SIGNED:</b>	06/23/2022

**Total Attachments: 7**

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page1.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page2.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page3.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page4.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page5.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page6.tif

source=G2204CA00 Universal Assignment OQP to OQP BIO INC#page7.tif

**UNIVERSAL ASSIGNMENT**

WHEREAS ONCOQUEST PHARMACEUTICALS INC., a corporation of the Republic of Korea, whose full address is 670-21 Sannae-ro, Sannae-myeon, Miryang-Si, Republic of Korea; hereinafter referred to as the "Assignor", is the exclusive owner of the patents and patents application(s) listed in Schedule A attached hereto and any inventions disclosed therein.

AND WHEREAS OQP BIO INC., a corporation of the Republic of Korea, whose full address is 4<sup>th</sup> Floor, Bonsol Building, 445, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea; hereinafter referred to as the "Assignee", has acquired from the Assignor the whole right, title and interest for the United States of America, Canada and all other countries in and to the said invention and in and to any Letters Patent that may be obtained therefor, and in and to said application(s).

NOW THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt of all of which is hereby acknowledged, the Assignor, by these presents confirms to have sold, assigned and transferred and do hereby sell, assign and transfer unto the said Assignee, the full and exclusive right to the said invention in the United States of America, Canada and all other countries and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor, and the entire right, title and interest in and to said application(s), and in and to any divisions, continuations, continuations-in-part and extensions of said application(s), together with the right to claim the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property based on said patent application(s), the right to take any legal action concerning the rights granted by any such patents or patent applications including the right to sue for any past or previous infringements.

Assignor agrees that he/she will without further consideration do all such things and execute all such documents as may be necessary or desirable to obtain and maintain patents for said invention and for additions and modifications thereto in any and all countries, and to vest title thereto in said Assignee, its successors, assigns and legal representatives or nominees.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, the assignee of the entire right, title and interest in and to the same, for its sole use and benefit, and for the use and benefit of its successors and assigns.

to the full end of the term for which Letters Patent may be granted as fully and entirely as the same would have been held by me had this assignment and sale not been made.


The undersigned hereby grant the firm of Benoit & Côté Inc., whose address is 560 Cremazie Blvd. East, Suite 300, Montreal, Quebec, H2P 1E8, Canada, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other Patent Offices in the world.

This assignment supersedes any previous assignments.

Les soussignés désirent que la présente cession soit en anglais. The undersigned request that the present assignment be in English.


SIGNED this 20 day of June, 2022, at Seoul, Republic of Korea  
(City, Country)

ONCOQUEST PHARMACEUTICALS INC.

By  \_\_\_\_\_

Name Seol Jung Ho

Title C.E.O

LEE CHANG HYUN   
Signature of Witness


LEE CHANG HYUN  
Name of Witness

G2204CA00

- 4 -


SIGNED this 20 day of June, 2022, at Seoul, Republic of Korea  
(City, Country)

OQP BIO INC.

By LEE CHANG HYUN 

Name Chase ChangHyun Lee

Title C.E.O

  
\_\_\_\_\_

Signature of Witness

Jun Sung Jin (Alex)  
Name of Witness

**SCHEDULE A**

<u>Country</u>	<u>Serial Number</u>	<u>Filing Date / Issue Date</u>
United States	6,716,966	April 6, 2004
United States	7,147,850	December 12, 2006
United States	6,689,355	February 10, 2004
Australia	2002358246	June 12, 2008
Canada	2,464,947	May 22, 2012
Switzerland	696871	January 15, 2008
United Kingdom	2397018	May 31, 2006
United States	8,038,994	October 18, 2011
United States	6,241,985	June 5, 2001
United States	8,945,566	February 3, 2015
United States	8,697,079	April 15, 2014
Europe	2331130	February 14, 2018
France	2331130	February 14, 2018
United Kingdom	2331130	February 14, 2018
WO	PCT/CA2015/050747	August 7, 2015
China	ZL 2015800534228	October 15, 2021
Europe	3177321	November 25, 2020
France	3177321	November 25, 2020
Germany	3177321	November 25, 2020
United Kingdom	3177321	November 25, 2020
Japan	6698084	April 30, 2020
United States	10,392,444	August 27, 2019

United States	62/034,915	August 8, 2014
WO	PCT/CA2016/050035	January 15, 2016
China	ZL2016800061159	August 10, 2021
Europe	3244924	July 4, 2021
France	3244924	July 4, 2021
Germany	3244924	July 4, 2021
United Kingdom	3244924	July 4, 2021
Japan	6854765	March 18, 2021
United States	10,975,163	April 13, 2021
United States	62/103,758	January 15, 2015
WO	PCT/CA2018/050095	January 26, 2018
China	2018800105245	January 26, 2018
Canada	3,051,913	January 26, 2018
Europe	3357509	September 6, 2021
France	3357509	September 6, 2021
Germany	3357509	September 6, 2021
United Kingdom	3357509	September 6, 2021
Japan	6999286	December 12, 2021
United States	10,537,636	January 21, 2020
United States	11,351,255	December 3, 2019
United States	62/455,114	February 6, 2017
Hong Kong	62020001769.2	January 26, 2018
WO	PCT/CA2022/050347	March 9, 2022
United States	63/159,013	March 10, 2021



G2204CA00

- 7 -

United States	63/318,835	March 11, 2022
WO	PCT/CA2021/057644	August 19, 2021
Unites States	17/406,171	August 19, 2021
Unites States	63/237,634	August 27, 2021
Unites States	63/320,844	March 17, 2022